Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report

[1]  James D. Murphy,et al.  Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature , 2021, Frontiers in Oncology.

[2]  O. Merimsky,et al.  COVID-19 Vaccine-Induced Radiation Recall Phenomenon , 2021, International Journal of Radiation Oncology*Biology*Physics.

[3]  R. Hustinx,et al.  Incidence, Risk Factors, and CT characteristics of Radiation Recall Pneumonitis induced byImmune Checkpoint Inhibitor in Lung Cancer. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  R. Gillies,et al.  Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine. , 2021, Cold Spring Harbor perspectives in medicine.

[5]  M. Scorsetti,et al.  Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. , 2020, European journal of cancer.

[6]  R. Zhao,et al.  Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  A. Cardona,et al.  Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy , 2020, Frontiers in Oncology.

[8]  C. Robert,et al.  Can radiation-recall predict long lasting response to immune checkpoint inhibitors? , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Jinming Yu,et al.  Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications , 2020, BMC Medicine.

[10]  F. Tanaka,et al.  Pembrolizumab-induced Radiation Recall Pneumonitis After the Resolution of Typical Asymptomatic Radiation Pneumonitis. , 2020, Journal of UOEH.

[11]  Yu Chen,et al.  Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature , 2020, Frontiers in Oncology.

[12]  Fengchun Zhang,et al.  Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis , 2020, BMC Medicine.

[13]  N. Ramaiya,et al.  Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  F. Hodi,et al.  Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features , 2019, Journal of Immunotherapy for Cancer.

[15]  K. McGovern,et al.  Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review , 2019, Future science OA.

[16]  K. Mitsumori,et al.  Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma , 2018, IJU case reports.

[17]  Tingting Liu,et al.  The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation , 2018, Radiation oncology.

[18]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[19]  Publisher's Note , 2018, Anaesthesia.

[20]  Y. Koh,et al.  Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Mazzone,et al.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death‐Ligand 1 Inhibitors in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Trials , 2017, Chest.

[22]  H. Iwase,et al.  Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report , 2016, International Cancer Conference Journal.

[23]  Yi-Wei Chen,et al.  Radiation recall pneumonitis induced by epidermal growth factor receptor‐tyrosine kinase inhibitor in patients with advanced nonsmall‐cell lung cancer , 2016, Journal of the Chinese Medical Association : JCMA.

[24]  C. Schraml,et al.  Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib , 2014, Melanoma research.

[25]  J. Soria,et al.  Targeted therapy-induced radiation recall. , 2013, European journal of cancer.

[26]  Sibel Kara,et al.  Radiation Recall Pneumonitis Caused by Erlotinib after Palliative Definitive Radiotherapy , 2012, Oncology Research and Treatment.

[27]  Junling Li,et al.  Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer , 2011, Radiation oncology.

[28]  Joe Y. Chang,et al.  ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. , 2010, International journal of radiation oncology, biology, physics.

[29]  H. Burris,et al.  Radiation Recall with Anticancer Agents , 2010, The oncologist.

[30]  D. de Ruysscher,et al.  Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. , 2010, International journal of radiation oncology, biology, physics.

[31]  A. Georgakilas,et al.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. , 2016, Toxicology research.